Table of Contents
•The purpose of this study is to analyze the Turkish life sciences market, which includes the pharmaceuticals segment and the clinical diagnostics segment. In 2013, the life sciences market revenue in Turkey was valued at $x billion, growing at x% from 2012 to 2013.
•Rapid economic growth and the healthcare transformation program have generated a significant increase in healthcare expenditure between 2003 and 2011 in Turkey. The national healthcare expenditure of Turkey grew from $xbillion in 2006 to $x billion in 2013, registering a strong year-over-year (YOY) growth of x% during this period. The life sciences market in Turkey will witness more growth than mature markets such as those in the United States, Japan, and Europe.
•Rapid socio-economic development in Turkey has resulted in an increasing trend in non-communicable diseases such as coronary diseases, cancer, diabetes, hypertension, obesity, and chronic obstructive pulmonary diseases. In 2012, coronary diseases, cancer, and respiratory diseases accounted for more than x% of the hospital deaths in Turkey.
•In 2003, a series of changes and innovations was implemented to qualify the health services provision in accordance with modern standards and to render it more efficient, effective, and accessible through the Health Transformation Program (HTP) by the fifty-ninth government.
•The pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe. This segment was valued at $x billion in 2013 and is expected to grow at a compound annual growth rate (CAGR) of x%, reaching $xbillion in 2018. Biotechnology-based drugs, diabetes, respiratory, and oncology drugs will exert the highest growth rates in the segment.
•The clinical diagnostics segment was valued at $x billion in 2013 and is expected to grow to at a CAGR of x%, reaching $xbillion by 2018.
•Following the centralization of the x former social security institutes (SSI) into a single SSI called Sosyal Guvenlik Kurumu (SGK), the social security system in Turkey underwent a significant transformation, resulting in a faster and more efficient health coverage system. Currently, % of Turkey’s total population is covered by the SGK.
•Turkey’s pharmaceuticals segment is dominated by international companies that constituted a combined share of x% in 2012. Local manufacturers, including Abdi Ibrahim (x% market share) and Bilim Ilac (x% market share), were among the top x pharmaceutical companies in Turkey.
•Because of huge capital investments and long research periods, Turkey does not conduct new molecule research. Research is mainly conducted on improving products and new formulations.
•This study provides an overview of the life sciences market in Turkey and its various therapeutic segments and product classes.
•For this research, life sciences market covers xmain segments: pharmaceuticals and clinical diagnostics.
•For the purpose of this research, the pharmaceuticals segment includes both drugs (small molecules) and biotechnology-based products (large molecules).
•In addition to market size and revenue forecast, detailed segment analysis has been provided for the pharmaceuticals segment with respect to investment trends, government reforms, regulatory policies, market shares, and key stakeholders.
•For the clinical diagnostics segment, top-line numbers and revenue forecasts have been provided.
•Revenues from medical devices and the private health care services segment are not included in this study.
•Other advanced medical technologies such as imaging, vital signs monitoring, and other tools used to diagnose and monitor patient conditions are not covered in this study.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
India Diagnostic Imaging Market Outlook to 2022 - Angio Suites, Bone Densitometers, Computed Tomography (CT) Systems, Contrast Agents, Contrast Media Injectors, Mammography Equipment, Mobile C-Arms, MRI ...
The top 10 cellular analysis market is expected to reach USD 41.34 billion by 2021 from USD 28.66 billion in 2016, at a CAGR of 7.6% during the forecast period. Factors such as increasing government support ...
This report studies the life science instruments and reagents market over the forecast period of 2017 to 2023. The life science instruments and reagents market is expected to grow at a high single digit ...